KD Logo

Chief Medical Officer, HAUSMAN DIANA sold 3,356 shares of Zentalis Pharmaceuticals Inc [ZNTL]

In a filing, Zentalis Pharmaceuticals Inc revealed its Chief Medical Officer HAUSMAN DIANA unloaded Company’s shares for reported $42353.0 on May 09 ’24. In the deal valued at $12.62 per share,3,356 shares were sold. As a result of this transaction, HAUSMAN DIANA now holds 373,876 shares worth roughly $4.36 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Epperly Melissa B, sold 2,573 shares, generating $29,435 in total proceeds. Upon selling the shares at $11.44, the Chief Financial Officer now owns 451,449 shares.

Before that, Gallagher Cam sold 1,173 shares. Zentalis Pharmaceuticals Inc shares valued at $13,419 were divested by the President at a price of $11.44 per share. As a result of the transaction, Gallagher Cam now holds 643,277 shares, worth roughly $7.51 million.

Wedbush downgraded its Zentalis Pharmaceuticals Inc [ZNTL] rating to a Neutral from a an Outperform in a research note published on November 08, 2023; the price target was decreased to $12 from $38. A number of analysts have revised their coverage, including Leerink Partners’s analysts, who decreased its forecast for the stock in early November from “an Outperform” to “a Market perform”. Cowen began covering ZNTL with “an Outperform” recommendation on July 12, 2022. Wells Fargo started covering the stock on April 06, 2022. It rated ZNTL as “an Overweight”.

Price Performance Review of ZNTL

On Tuesday, Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] saw its stock fall -0.68% to $11.67. Over the last five days, the stock has lost -5.20%. Zentalis Pharmaceuticals Inc shares have fallen nearly -22.97% since the year began. Nevertheless, the stocks have fallen -56.60% over the past one year. While a 52-week high of $31.46 was reached on 02/28/24, a 52-week low of $9.56 was recorded on 04/25/24. SMA at 50 days reached $13.46, while 200 days put it at $16.30. A total of 0.5 million shares were traded, compared to the trading of 0.67 million shares in the previous session.

Levels Of Support And Resistance For ZNTL Stock

The 24-hour chart illustrates a support level at 11.23, which if violated will result in even more drops to 10.80. On the upside, there is a resistance level at 12.39. A further resistance level may holdings at 13.12. The Relative Strength Index (RSI) on the 14-day chart is 41.75, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.30, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 55.09%. Stochastics %K at 54.22% indicates the stock is a holding.

Most Popular